Reaction

Hepatic Pain reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,221 reports · 120 co-occurring drugs

As of the last recalculation, Hepatic Pain appears in 4,221 FAERS reports alongside 120 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 25.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Octreotide Acetate	153	25.5	25.6
Regorafenib	39	16.7	16.8
Lanreotide Acetate	26	16.4	16.5
Glecaprevir And Pibrentasvir	34	15.4	15.4
Peginterferon Alfa-2A	146	13.8	13.8
Ursosiol	48	12.3	12.3
Velpatasvir And Sofosbuvir	29	11.2	11.2
Ursodiol	48	11.0	11.0
Ribavirin	137	10.8	10.8
Sorafenib	45	10.8	10.8
Ribociclib	53	8.4	8.4
Ledipasvir And Sofosbuvir	32	8.3	8.3
Esomeprazole Magnesium Capsule, Delayed Release	23	7.9	7.9
Esomeprazole Magnesium Delayed Release Capsules	23	7.9	7.9
Esomeprazole Magnesium Dihydrate	23	7.8	7.8
Ado-Trastuzumab Emtansine	13	7.6	7.6
Sofosbuvir	26	6.5	6.5
Captopril	12	6.2	6.2
Naltrexone	38	6.1	6.1
Everolimus	62	6.1	6.1
Trifluridine And Tipiracil	12	5.5	5.5
Entecavir	13	5.5	5.5
Methocarbamol	25	5.5	5.5
Pitavastatin Calcium	11	5.3	5.3
Inclisiran	8	4.9	4.9
Goserelin	12	4.4	4.4
Anastrozole Tablets	19	4.4	4.4
Dolutegravir Sodium	8	4.4	4.4
Nilotinib	26	4.4	4.4
Elexacaftor, Tezacaftor, And Ivacaftor	11	4.4	4.4
Irinotecan Hydrochloride	11	4.2	4.2
Deferasirox	22	4.1	4.1
Lisdexamfetamine Dimesylate	27	4.1	4.1
Sunitinib Malate	32	4.0	4.0
Lenvatinib	26	3.9	3.9
Fulvestrant	26	3.9	3.9
Doxepin	8	3.9	3.9
Diclofenac Sodium 1%	28	3.9	3.9
Diclofenac Sodium Topical	28	3.9	3.9
Diclofenac Sodium Topical Gel, 1%	28	3.9	3.9
Lapatinib	12	3.8	3.8
Loperamide Hydrochloride And Dimethicone	24	3.7	3.7
Exemestane	16	3.7	3.7
Cholestyramine	9	3.7	3.7
Avapritinib	9	3.7	3.7
Posaconazole Delayed-Release	8	3.6	3.6
Darunavir	11	3.6	3.6
Buprenorphine Hydrochloride, Naloxone Hydrochloride	17	3.5	3.5
Fam-Trastuzumab Deruxtecan-Nxki	7	3.4	3.4
Diroximel Fumarate	8	3.3	3.3
Rifaximin	14	3.3	3.3
Sotalol Hydrochloride	11	3.3	3.3
Thyroid, Porcine	7	3.2	3.2
Prochlorperazine Maleate	6	3.2	3.2
Abemaciclib	13	3.2	3.2
Loperamide Hydrochloride	29	3.2	3.2
Busulfan	10	3.1	3.1
Finasteride	37	3.0	3.0
Piperacillin Sodium,Tazobactam Sodium	16	3.0	3.0
Teriflunomide	27	3.0	3.0
Everolimus Tablets	10	2.9	2.9
Ibuprofen Tablets, Coated	25	2.9	2.9
Ibuprofen Sodium	25	2.9	2.9
Letrozole Tablets	28	2.9	2.9
Vemurafenib	7	2.9	2.9
Tenofovir Disoproxil Fumarate Tablets	5	2.9	2.9
Ticagrelor	18	2.8	2.8
Oxazepam	12	2.8	2.8
Bosutinib	5	2.7	2.7
Cannabidiol	13	2.7	2.7
Nintedanib	17	2.7	2.7
Amlodipine Besylate And Valsartan	6	2.7	2.7
Capecitabine	49	2.7	2.7
Carboxymethylcellulose Sodium	5	2.6	2.6
Pertuzumab	14	2.5	2.5
Fosaprepitant Dimeglumine	7	2.5	2.5
Asfotase Alfa	5	2.5	2.5
Dronedarone	5	2.4	2.4
Trastuzumab	33	2.4	2.4
Nirmatrelvir And Ritonavir	26	2.4	2.4
Cenobamate	4	2.4	2.4
Dabrafenib	10	2.3	2.3
Insulin Degludec	11	2.3	2.3
Niraparib	10	2.2	2.2
Bevacizumab	54	2.2	2.2
Temozolomide	9	2.1	2.1
Ruxolitinib	30	2.1	2.1
Gemcitabine Hydrochloride	22	2.1	2.1
Trametinib	10	2.0	2.0
Cabozantinib	19	2.0	2.0
Oral Semaglutide	29	2.0	2.0
Tenofovir Disoproxil Fumarate	13	1.9	1.9
Eltrombopag Olamine	9	1.9	1.9
Panitumumab	6	1.9	1.9
Gemcitabine	15	1.9	1.9
Ivacaftor	3	1.9	1.9
Fingolimod Hcl	32	1.8	1.8
Abiraterone	5	1.8	1.8
Ozanimod Hydrochloride	3	1.8	1.8
Palbociclib	34	1.8	1.8
Diclofenac Potassium, Film Coated	3	1.8	1.8
Diclofenac Potassium Tablets	3	1.8	1.8
Orlistat	9	1.7	1.7
Travoprost	3	1.7	1.7
Voclosporin	3	1.7	1.7
Durvalumab	7	1.7	1.7
Gefitinib	3	1.6	1.6
Alirocumab	8	1.6	1.6
Encorafenib	3	1.5	1.5
Ipilimumab	13	1.5	1.5
Pazopanib Hydrochloride	8	1.5	1.5
Pirfenidone	12	1.5	1.5
Atezolizumab	11	1.4	1.4
Voxelotor	6	1.3	1.3
Varenicline Tartrate	19	1.2	1.2
Lutetium Lu 177 Vipivotide Tetraxetan	3	1.1	1.1
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	4	1.1	1.1
Evolocumab	32	1.0	1.0
Guselkumab	7	1.0	1.0
Tirzepatide	21	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.